帕博利珠单抗联合GX-188E治疗HPV阳性晚期宫颈癌的二期试验中期结果
这项开放标签、单臂、二期试验在韩国七家医院纳入36例复发或晚期HPV-16/18阳性宫颈癌患者,接受GX-188E治疗性DNA疫苗联合帕博利珠单抗治疗。中期分析中26例可评估患者24周总体缓解率为42%(95%CI 23-63),其中完全缓解15%、部分缓解27%,安全性可控。
要点
- 联合方案在复发/晚期HPV阳性宫颈癌中显示初步抗肿瘤活性,24周ORR达42%。
- 治疗相关不良事件多为1-2级,3-4级发生率为11%。
- 该联合策略可能成为该人群的新治疗选择,试验仍在进行中。
核心结论
- GX-188E治疗性DNA疫苗联合帕博利珠单抗在复发或晚期宫颈癌中安全且不良事件可控。
- 中期分析显示该联合方案具有初步抗肿瘤活性,可能代表新的潜在治疗选择。
研究设计与样本
- 开放标签、单臂、二期试验,在韩国七家医院招募患者。
- 纳入36例复发或晚期、不可手术的HPV-16或HPV-18阳性宫颈癌患者,ECOG评分0或1,标准治疗失败后。
- 患者接受肌肉注射GX-188E 2 mg(第1、2、4、7、13、19周,第46周可选)联合静脉帕博利珠单抗200 mg每3周一次,最长2年或至疾病进展。
- 主要终点为24周内研究者按RECIST v1.1评估的总体缓解率,在至少接受45天治疗且有至少一次基线后肿瘤评估的患者中分析。
主要发现
- 26例可评估患者中,11例(42%;95%CI 23-63)在24周时达到总体缓解。
- 4例(15%)完全缓解,7例(27%)部分缓解。
- 36例患者中16例(44%)发生任何级别治疗相关不良事件,4例(11%)发生3-4级治疗相关不良事件。
- 3级不良事件包括AST升高、晕厥、心包积液和高钾血症各1例,4级ALT升高1例。
- 未报告治疗相关死亡。
关键数值与推荐
- 24周总体缓解率:42%(95%CI 23-63),基于26例可评估患者。
- 完全缓解率15%(4/26),部分缓解率27%(7/26)。
- 任何级别治疗相关不良事件发生率44%(16/36),3-4级发生率11%(4/36)。
临床怎么用
- 对于标准治疗失败的复发或晚期HPV-16/18阳性宫颈癌患者,可考虑GX-188E疫苗联合帕博利珠单抗作为潜在治疗选择。
- 治疗期间需监测治疗相关不良事件,包括肝酶升高、心包积液、晕厥和高钾血症。
局限性
- 单臂设计,无对照组,样本量较小(36例入组,26例可评估)。
- 仅纳入HPV-16或HPV-18阳性患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival outcomes for patients with recurrent or advanced cervical cancer are poor. Pembrolizumab has been approved for the treatment of recurrent or metastatic cervical cancer, with an overall response rate of 14·3%. GX-188E vaccination has been shown to induce human papillomavirus (HPV) E6-specific and E7-specific T-cell responses and cervical lesion regression in patients with cervical precancer. We aimed to investigate whether a combination of GX-188E therapeutic DNA vaccine plus pembrolizumab showed antitumour activity against recurrent or advanced cervical cancer. METHODS: In this open-label, single-arm, phase 2 trial, patients with recurrent or advanced, inoperable cervical cancer, who were aged 18 years or older with Eastern Cooperative Oncology Group performance status of 0 or 1 and histologically confirmed recurrent or advanced HPV-positive (HPV-16 or HPV-18) cervical cancer, and who had progressed after available standard-of-care therapy were recruited from seven hospitals in South Korea. Patients received intramuscular 2 mg GX-188E at weeks 1, 2, 4, 7, 13, and 19, with one optional dose at week 46 that was at the investigator's discretion, and intravenous pembrolizumab 200 mg every 3 weeks for up to 2 years or until disease progression. The primary endpoint was the overall response rate within 24 weeks assessed by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 in patients who received at least 45 days of treatment 45 days of treatment with at least one post-baseline tumour assessment, and this is the report of a planned interim analysis. This trial is registered with ClinicalTrials.gov, NCT03444376. FINDINGS: Between June 19, 2018, and March 20, 2020, 36 patients were enrolled and received at least one dose of the study treatment. 26 patients were evaluable for interim activity assessment, with at least one post-baseline tumour assessment at week 10. At the data cutoff date on March 30, 2020, median follow-up duration was 6·2 months (IQR 3·5-8·1). At 24 weeks, 11 (42%; 95% CI 23-63) of 26 patients achieved an overall response; four (15%) had a complete response and seven (27%) had a partial response. 16 (44%) of 36 patients had treatment-related adverse events of any grade and four (11%) had grade 3-4 treatment-related adverse events. Grade 3 increased aspartate aminotransferase, syncope, pericardial effusion, and hyperkalaemia, and grade 4 increased alanine aminotransferase were reported in one patient each. No treatment-related deaths were reported. INTERPRETATION: Treatment with GX-188E therapeutic vaccine plus pembrolizumab for patients with recurrent or advanced cervical cancer was safe and treatment-related adverse events were manageable. This combination therapy showed preliminary antitumour activity in this interim analysis, which could represent a new potential treatment option for this patient population. This trial is ongoing. FUNDING: National OncoVenture.
引用
- Youn JW, Hur SY, Woo JW, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020. PMID: 33271094. doi:10.1016/S1470-2045(20)30486-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。